- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04629716
Reactions of Older Adults Driving After Cannabis Exposure (ROAD ACE)
Medical Marijuana Use and Driving Performance: A Test of Psychomotor Function in Adults 50 and Older
Study Overview
Detailed Description
The proposed study is a prospective repeated measures experimental study designed to test medical marijuana use as the exposure variable in adults age 50 and older and driving errors in response time, attention, and executive functions as the primary outcome. Secondary outcomes include: adverse effects. Participants will complete 3 assessments over a 3-month time period. The 3 assessment time points are: baseline (T1) prior to starting medical marijuana, 1 month post-medical marijuana initiation (T2), and 3 months post-medical marijuana initiation (T3). Electronic Medical Review (EMR) will be conducted at baseline, 1 and 3 months. In addition, potentially confounding disease, treatment, and sociodemographic characteristics will be examined. Data will be collected in a manner that is consistent with transparent reporting as mandated by CONSORT guidelines. Finite mixture modeling and generalized linear modeling accounting for individual and group level outcomes will be used to test the study hypotheses.
Participants will be N=60 adults ages 50 and older who have newly registered with the state of Florida to obtain medical marijuana (n=30) or age, race, sex matched non-marijuana user controls (n=30).
Intervention Group Recruitment. Participants will be recruited from Medical Marijuana Treatment Clinics of Florida's (MMTC) Gainesville location. Recruitment for this study begins pre-medical marijuana exposure. To obtain medical marijuana in the state of Florida there are four steps:
- Step 1: Determine Eligibility: Eligibility for medical marijuana use must be determined by a qualified physician. A patient must first seek treatment from a qualified physician. MMTC has qualified physicians who determine patient eligibility.
- Step 2: Medical Marijuana Registration: Once the MMTC physician determines the patient is eligible for medical marijuana, the physician then inputs the patient's information and the medical marijuana order information into the Medical Marijuana Use Registry. MMTC physicians complete this process during the eligibility appointment. Recruitment for the current project begins at step 2 which is prior to any exposure to medical marijuana. Participants will undergo a brief screen during their visit with the MMTC physician to determine if they meet eligibility criteria (See Eligibility Criteria in Human Study Record 1 per new NIH guidelines). Eligibility screening procedures will be IRB-approved and will not collect any identifying information. Self-report questionnaires will be use to discern eligibility. Eligibility will be confirmed using medical records at enrollment. If MMTC patients meet eligibility criteria, they will be given the opportunity to meet with the study research assistant (RA) to learn more about the project. Participants will be provided a detailed description of the study, and the research assistant will obtain permission to follow up with the patient (by phone or text) in order to track their progress on obtaining their registry identification card.
- Step 3: Medical Marijuana Use Registry Identification Card: Once a physician has input the patient's information into the Medical Marijuana Use Registry (i.e. step 2), the patient is able to apply for a medical marijuana card. This process takes approximately 10-14 days. Participants will be instructed to schedule their baseline study visit prior to obtaining their first dose of medical marijuana. At the baseline appointment the study staff will obtain informed consent and complete the biobehavioral assessment measures, and participants will complete their first drive.
- Step 4: Dispensation of Medical Marijuana: Once the patient receives the medical marijuana card, the patient is then able to fill their first order for medical marijuana at a dispensary. The Medical Marijuana Use Registry will track patients' dose, frequency, type of medical marijuana received, and route of administration. After obtaining their medical marijuana card and filling their first dispensation, the investigators will track patients through MMTC and follow patients for 3 months post medical marijuana initiation.
Control Group Recruitment. Control participants will be age, race, and sex matched adults 50 and older with a diagnosis of chronic or severe pain recruited from the community using flyers/handouts; newspaper/Internet advertisements; in-person lectures and events; and contact via mail, e-mail, and the infrastructure and support of Oak Hammock at the UF, a residential retirement community. The investigators will also phone individuals enrolled in the University of Florida HealthStreet and Clinical and Translational Science Institute's (CTSI) Integrated Data Repository, a database organizing clinical information across UF Health's clinical and research programs.
Attrition is a large concern in an observational trial of this rigor. Within the lab, based on prior experience the investigators anticipate between 15-20% dropout by time point 3. Therefore, the investigators anticipate recruiting 72 participants (62+20%) in order to achieve our goal. However, there are numerous strategies that the investigators have used in the past and will put in place to increase retention.
Test of Aim 1 (Driving Simulator)
Driving Simulator Data will be collected via the kinematic functionality of the high-fidelity driving simulator (e.g. speed in mph, braking, swerving, lateral lane positioning, etc.) and also through observing the performance of the driver via a trained evaluator who will use the playback function of the simulator to scrutinize the errors. The drive will begin with a 5-minute acclimation scenario which is designed to train drivers on aspects of simulator operation and help them adjust to driving in a simulator. The simulator acclimation drive addresses lane keeping on straight and curved roads, braking, changing lanes, use of side and rear-view mirrors, and stopping. After the 5-minute acclimation scenario, the driver will drive the main drive for 10 minutes. Three scripted events will be randomly presented to the drivers to control for learning effects.
- Event 1. To assess response time, during the drive a vehicle is pulling out in front of the driver and the driver's behavior is measured via braking milliseconds (ms) and swerving (standard deviation {SD} of lateral deviation from center lane).
- Event 2. Next, using an established protocol, during the course of the drives divided attention (being aware of the traffic and surrounding while focusing on critical stimulus) is assessed via a triangle appearing on the screen and the participant needing to press a button (i.e. respond) as soon as they see it (measured in ms and number of omissions and commissions).
- Event 3. Lastly, executive functions are measured by providing the driver with instructions before the drive (i.e. to turn into a KFC, pull into a parking bay, and when it is safe to do so, exit the lot and merge into the flow of traffic (measured via visual scanning (yes/no) speed regulation (mph over or under the speed limit), adjustment to stimuli (notice the KFC (yes/no), slow down (mph), signaling (yes/no), vehicle positioning (buffer around the vehicle yes/no), and gap acceptance (narrow or tight via ms)69, 70,121-122. Participants will be scored on number of tasks completed correctly.
Within Subject Analysis. To answer the primary question of this proposal, "Does medical marijuana use affect driving performance?," the investigators will use repeated measures ANOVA. The investigators will examine within subject differences on measures at all 3 time points in order to answer the question of whether medical marijuana impacts response time, divided attention, and executive functions. Using a repeated measures ANOVA, time will serve as the independent variable and continuous measures of driving errors (as defined above) as the outcomes. Power Analysis: The investigators computed the power to detect a medium effect size of 0.5 standard deviations across groups. Assuming a correlation of 0.2 across the repeated measures at three time points, the standard deviation of the average of three measures is 0.683 times the standard deviation of one measure. Therefore, with 30 per group the investigators can detect a difference in this average of 0.5 times the standard deviation of one measure, using a two-sided test with 80% power. The investigators calculated Cohen's d using Dr. Classen's prior work that examined total driving errors and specific errors (lane maintenance) in healthy controls (M=24.08 SD=12.38) and (M=5.78 SD=4.26) versus Parkinson's patients (M=31.99 SD=22.01) and (M=10.23 SD=9.26), which yielded a Cohen's d of .46-.65 (medium effect size)59; therefore, the investigators will be powered to detect this medium effect size.
Between Group Analyses Comparisons between medical marijuana users and control group participants will be examined using independent samples t-test (controlling for unequal variances using Levene's test) or Mann-Whitney U tests if the data are nonparametric in order to rule out change over time as an explanation of findings. No difference is hypothesized between groups at baseline. At time 2 and 3 the control group is hypothesized to have higher average response time, divided attention reaction time, and scores on divided attention tasks completed correctly than medical marijuana users.
Test of Aim 2 (Adverse Effects) Adverse Effects. In this study, adverse effects are defined as undesired effects that occur when medication is administered. The investigators will use Scripted Prompting, a proactive form of adverse effect capture recognized in the field. This method is designed to elicit adverse effects without biasing the patient; it is a standardized question that allows participants to report important symptoms without being influenced by suggestion. For this study the investigators will ask: "Since initiating medical marijuana, are you having any problems related to use?"
To describe factors associated with adverse effects, the investigators will report the number of adverse effects reported by participants at time points 2 and 3. Adverse Effects will be defined as both a count variable and a binary variable such that absence or presence of adverse effects will be coded as 0/1 respectively. The investigators will then use Poisson and Logistic regression methods to examine analyze the bivariate association between dosage, frequency of use, route of administration (pills, vape, etc.), and type of product (THC v. CBD). Power Statement: The goal of aim 2 is to examine the strength of the association between factors of medical marijuana use and adverse effects. Currently, the literature does not contain data regarding the strength of the association between medical marijuana use and adverse effects or how dosage, frequency of use, and route of administration are associated with adverse effects. As there may be insufficient power for statistical significance using the proposed analyses above, effect size estimates will be used to examine the strength of the association between variables. With 30 per group, the investigators can detect a difference of 0.73 standard deviations using a two-sided test with 80% power.
Exploratory Aim: Examine factors associated with study feasibility (enrollment and retention) for development of a future R01. The investigators will describe the association between socio-demographic factors (i.e. gender, race, and education) and enrollment and retention in the intervention condition in order to identify ways to improve study feasibility. The investigators will use chi-square for dichotomous variables and Pearson correlations for continuous variables to examine associations between sociodemographic factors and study enrollment (number screened who meet criteria versus number enrolled) and retention (number enrolled versus number completing all 3 time points). This method will allow us to identify candidate predictors of enrollment and attrition to inform the investigative team about strengthening recruitment/retention efforts for specific subgroups.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Nicole Ennis, PhD
- Phone Number: 850-644-2334
- Email: nicole.ennis@med.fsu.edu
Study Contact Backup
- Name: Katie Kloss, BA
- Phone Number: 352-234-3879
- Email: katie.kloss@med.fsu.edu
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32608
- Smart House at Oak Hammock
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participant is aged 50 or older
- Participant reports severe and/or chronic pain
- Participant is newly registered to the Medical Marijuana Use Registry in Florida (intervention group only)
- Participant has no prior history with medical marijuana use (intervention group only)
Exclusion Criteria:
- Participant lacks fluency in English
- Participant is unwilling to provide information for follow-up
- Participant plans to leave the area within 3 months
- Participant is unable to provide informed consent due to cognitive impairment
- Participant is unwilling to complete necessary study procedures
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Intervention
The intervention group will be comprised of adults 50 and older who report severe or chronic pain, are newly registered for the Medical Marijuana Registry in the State of Florida, have no prior history of medical marijuana use, can communicate in English, and are willing and able to complete study procedures.
The control group will be age, sex, and race matched.
The primary study outcome is simulated driving performance (i.e.
errors in response time, attention, and executive functioning tasks that predict on-road performance).
Secondary outcomes include adverse effects.
|
Medical marijuana is defined by Florida state statue 381.986 as all parts of any plant of the genus Cannabis, whether growing or not; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant or its seeds or resin, including low-THC cannabis, which are dispensed from a medical marijuana treatment center for medical use by a qualified patient.
Other Names:
|
Control
The control group will be comprised of adults 50 and older who report severe or chronic pain, have no prior history of medical marijuana use, can communicate in English, and are willing and able to complete study procedures.
The control group will be age, sex, and race matched.
The primary study outcome is simulated driving performance (i.e.
errors in response time, attention, and executive functioning tasks that predict on-road performance).
Secondary outcomes include adverse effects.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Simulated driving performance
Time Frame: 3 months
|
Studies of driving performance using driving simulators have been shown to be a valid predictor of on-road driving performance.
Driving simulators allow for the systematic presentation of events and the manipulation of variables, which offers experimental control that is impossible on the road.
Driving simulators also offer optimal stimulus presentation which allows for analysis of both healthy and impaired drivers under similar conditions.
Therefore, using a driving simulator, the investigators can examine outcomes such as response time, attention, and executive functions using valid real world tasks.
These outcomes will be recorded automatically using the driving simulator itself.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse effects
Time Frame: 3 months
|
In this study, adverse effects are defined as undesired effects that occur when the medication is administered.
The investigators will use Scripted Prompting, a proactive form of adverse effect capture recognized in the field.
This method is designed to elicit adverse effects without biasing the patient; it is a standardized question that allows participant to report important symptoms without being influenced by suggestion.
For this study, the investigators will ask: "Since initiating medical marijuana, are you having any problems related to use?"
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nicole Ennis, PhD, Florida State University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00001659
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pain
-
Pain ConcernThe Thistle Foundation; Health and Social Care Alliance Scotland (the ALLIANCE) and other collaboratorsCompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain HipUnited Kingdom
-
Consorci Sanitari de l'Alt Penedès i GarrafRecruitingChronic Post Operative Pain | Chronic Post-surgical Pain | Chronic Knee PainSpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of Alabama, TuscaloosaPatient-Centered Outcomes Research Institute; East Carolina University; Whatley...CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to InjuryUnited States
-
University of UtahRecruitingChronic Pain | Chronic Pain Syndrome | Widespread Chronic PainUnited States
-
Evolve Restorative CenterFlowonix Medical; Celéri Health, Inc.; Advanced Infusion SolutionsCompletedPain, Chronic | Pain, Intractable | Chronic Nonmalignant PainUnited States
-
Assiut UniversityNot yet recruiting
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Vastra Gotaland RegionActive, not recruitingPain, Chronic | Widespread Chronic PainSweden
-
Istanbul UniversityCompletedLow Back Pain, Mechanical, Biofeedback, Pain, Chronic
Clinical Trials on Medical Cannabis
-
HaEmek Medical Center, IsraelTechnion, Israel Institute of Technology; Syqe MedicalNot yet recruitingChemotherapy-induced Peripheral NeuropathyIsrael
-
University of ManitobaCanadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS); The Canadian Collaborative for Childhood Cannabinoid TherapeuticsRecruitingEpilepsy | Cancer | Neurodevelopmental DisordersCanada
-
Eli Sprecher, MDRecruitingHealthy | Crohn Disease | Ulcerative Colitis | PouchitisIsrael
-
Massachusetts General HospitalCompletedDepression | Pain | Insomnia | AnxietyUnited States
-
M. H MediCane Ltd.RecruitingDementia | Alzheimer Disease | Agitation,Psychomotor | Disruptive BehaviorIsrael
-
University Health Network, TorontoShoppers Drug Mart; integrated medhealth communicationRecruitingDepression | Epilepsy | Pain | Sleep | AnxietyCanada
-
University of Colorado, DenverColorado Department of Public Health and EnvironmentUnknownEpilepsy, Unspecified, Refractory (Medically)United States
-
TO PharmaceuticalsWithdrawn
-
Universita degli Studi della BasilicataSan Carlo Public Hospital, Potenza, ItalyCompleted
-
Sheba Medical CenterRecruitingParkinson Disease | Bladder, OveractiveIsrael